The shortage of Novo Nordisk’s (NVO) blockbuster diabetes and weight-loss drugs is officially over, according to the U.S.

Federal regulators say shortages of Ozempic and Wegovy have been resolved, as supplies of popular diabetes and obesity ...

The agency first declared a shortage of semaglutide, the main ingredient used to make Ozempic and Wegovy, in 2022.

Following the resolution of Eli Lilly’s tirzepatide shortage in October, the FDA has officially declared an end to the supply ...

The FDA has declared an end to the shortage of Novo Nordisk’s blockbuster drug semaglutide, threatening the ability for ...

Two Omaha women lost more than 300 lbs. combined with injections of a GLP-1 drug, which are used increasingly for weight loss ...

Demand GLP-1 Medications as Prescription Drug Market Grows SCHAUMBURG, IL, Feb. 20, 2025 (GLOBE NEWSWIRE) -- Giftify, Inc. (NASDAQ:GIFT) (the "Company"), the owner and operator of CardCash.com and ...

Novo Nordisk thrives despite competition and explore its breakthrough amycretin study. Read here to know why we rate NVO ...

A new study suggests that medications that have transformed the treatment of obesity may also help people drink less alcohol.

Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...

Compounded weight-loss medications, such as those promoted in the Hims & Hers commercial, aren’t approved by the Food and Drug Administration.

To lose weight, you need to be in a calorie deficit ... your RMR results with your activity level based on the following chart: 1.2 - Sedentary (little to no exercise) 1.375 - Lightly active ...